Swiss National Bank Sells 126,200 Shares of UiPath Inc. (NYSE:PATH)

Swiss National Bank cut its holdings in UiPath Inc. (NYSE:PATHFree Report) by 9.9% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,154,900 shares of the healthcare company’s stock after selling 126,200 shares during the quarter. Swiss National Bank’s holdings in UiPath were worth $19,760,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in PATH. BlackRock Inc. boosted its holdings in UiPath by 32.1% in the second quarter. BlackRock Inc. now owns 23,376,854 shares of the healthcare company’s stock valued at $387,354,000 after acquiring an additional 5,681,577 shares during the last quarter. Altimeter Capital Management LP boosted its holdings in UiPath by 175.4% in the first quarter. Altimeter Capital Management LP now owns 8,275,000 shares of the healthcare company’s stock valued at $71,579,000 after acquiring an additional 5,270,194 shares during the last quarter. Senvest Management LLC boosted its holdings in UiPath by 188.4% during the second quarter. Senvest Management LLC now owns 6,027,933 shares of the healthcare company’s stock worth $99,883,000 after buying an additional 3,937,951 shares during the last quarter. Millennium Management LLC boosted its holdings in UiPath by 899.5% during the fourth quarter. Millennium Management LLC now owns 4,049,999 shares of the healthcare company’s stock worth $51,475,000 after buying an additional 3,644,799 shares during the last quarter. Finally, State Street Corp boosted its holdings in UiPath by 251.1% during the second quarter. State Street Corp now owns 4,996,369 shares of the healthcare company’s stock worth $90,884,000 after buying an additional 3,573,238 shares during the last quarter. 59.04% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

PATH has been the topic of a number of recent analyst reports. Barclays raised their target price on UiPath from $21.00 to $23.00 and gave the stock an “equal weight” rating in a report on Friday, January 12th. Royal Bank of Canada raised their target price on UiPath from $19.00 to $24.00 and gave the stock a “sector perform” rating in a report on Friday, December 1st. Mizuho raised their target price on UiPath from $18.00 to $22.00 and gave the stock a “neutral” rating in a report on Friday, December 1st. Wells Fargo & Company raised their price target on UiPath from $18.00 to $20.00 and gave the stock an “equal weight” rating in a research report on Friday, December 1st. Finally, Needham & Company LLC raised their price target on UiPath from $20.00 to $25.00 and gave the stock a “buy” rating in a research report on Friday, December 1st. Eight investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, UiPath has a consensus rating of “Hold” and an average target price of $22.32.

View Our Latest Research Report on UiPath

UiPath Price Performance

Shares of UiPath stock opened at $26.35 on Friday. The business’s 50 day simple moving average is $23.86 and its 200 day simple moving average is $19.24. UiPath Inc. has a 52-week low of $12.38 and a 52-week high of $26.94.

UiPath (NYSE:PATHGet Free Report) last announced its earnings results on Thursday, November 30th. The healthcare company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.05. UiPath had a negative return on equity of 5.98% and a negative net margin of 12.51%. The business had revenue of $325.92 million for the quarter, compared to analyst estimates of $315.54 million. As a group, equities analysts forecast that UiPath Inc. will post -0.22 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Ashim Gupta sold 16,000 shares of UiPath stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $22.47, for a total transaction of $359,520.00. Following the completion of the transaction, the chief financial officer now directly owns 103,505 shares in the company, valued at approximately $2,325,757.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CFO Ashim Gupta sold 16,000 shares of the business’s stock in a transaction on Monday, February 5th. The stock was sold at an average price of $22.47, for a total value of $359,520.00. Following the completion of the sale, the chief financial officer now directly owns 103,505 shares in the company, valued at approximately $2,325,757.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Brad Brubaker sold 10,000 shares of the business’s stock in a transaction on Monday, December 18th. The shares were sold at an average price of $25.62, for a total value of $256,200.00. Following the completion of the sale, the insider now owns 587,608 shares of the company’s stock, valued at $15,054,516.96. The disclosure for this sale can be found here. Insiders have sold 866,000 shares of company stock valued at $19,382,520 in the last 90 days. 31.03% of the stock is currently owned by insiders.

UiPath Company Profile

(Free Report)

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.

Read More

Want to see what other hedge funds are holding PATH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for UiPath Inc. (NYSE:PATHFree Report).

Institutional Ownership by Quarter for UiPath (NYSE:PATH)

Receive News & Ratings for UiPath Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UiPath and related companies with MarketBeat.com's FREE daily email newsletter.